Nurix Therapeutics' Gwenn Hansen sells 1,452 shares

The Chief Scientific Officer's exercise-and-sale sequence was reported under a previously adopted Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen exercised options covering 1,452 shares at an exercise price of $1.86 per share on October 15, 2026, acquired 1,452 common shares, and sold those shares at $25.00 per share. The transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Hansen. Following the exercise, her reported option position was 59,406 shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,452 shares ($34K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Hansen Gwenn

Role Chief Scientific Officer

Sold 1,452 shs ($36K)

Approx. gross sale proceeds $36K

Approx. exercise cost $3K

Approx. pre-tax spread $34K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy) F1, F2	1,452	$0.00	$0.00
Exercise	Common Stock F1	1,452	$1.86	$3K
Sale	Common Stock F1	1,452	$25.00	$36K

Holdings After Transaction: Employee Stock Option (right to buy) — 59,406 contracts (Direct); Common Stock — 117,227 shares (Direct)

Footnotes (2)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
2. F2. The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.

Key Figures

Options exercised: 1,452 shares Exercise price: $1.86 per share Common shares sold: 1,452 shares +3 more

6 metrics

Options exercised 1,452 shares October 15, 2026

Exercise price $1.86 per share Option exercise on October 15, 2026

Common shares sold 1,452 shares October 15, 2026

Sale price $25.00 per share Sale on October 15, 2026

Reported option position after transaction 59,406 shares Following the October 15, 2026 exercise

Option expiration date August 28, 2029 Employee stock option

Key Terms

Rule 10b5-1 trading plan, Employee Stock Option (right to buy), exercise price

3 terms

Rule 10b5-1 trading plan regulatory

"effected pursuant to a Rule 10b5-1 trading plan previously adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Option (right to buy) technical

"Employee Stock Option (right to buy)"

exercise price financial

"at an exercise price of $1.86 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NRIX shares did Gwenn Hansen sell, and at what price?

Gwenn Hansen sold 1,452 common shares at $25.00 per share on October 15, 2026. The sale was part of the reported option-exercise sequence and was effected pursuant to a Rule 10b5-1 trading plan previously adopted by Hansen.

How many NRIX shares did Gwenn Hansen acquire through option exercise?

Hansen acquired 1,452 common shares through an option exercise on October 15, 2026, at an exercise price of $1.86 per share.

How many options did Gwenn Hansen hold after the NRIX exercise?

After the October 15, 2026 exercise, Hansen's reported option position covered 59,406 shares. The option's expiration date was August 28, 2029.

When did Gwenn Hansen's NRIX stock option vest?

The option vested as to 1/48 of the total shares monthly, beginning June 10, 2019, and was fully vested on May 10, 2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/15/2026 - 05:00 PM EDT Accepted by SEC EDGAR 10/15/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hansen Gwenn

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2026		M(1)		1,452	A	$1.86	118,679	D
Common Stock	10/15/2026		S(1)		1,452	D	$25	117,227	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.86	10/15/2026		M(1)			1,452	(2)	08/28/2029	Common Stock	1,452	$0	59,406	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen	10/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)